<?xml version="1.0" encoding="UTF-8"?>
<p>In Botswana, subtype C patients treated with ZDV/ddI developed an atypical thymidine analogue resistance pathway (67N/70R/215Y) compared to subtype B [
 <xref ref-type="bibr" rid="b23-viruses-02-02493">23</xref>], that was also not observed in patients with subtype C in India, South Africa, or Malawi [
 <xref ref-type="bibr" rid="b24-viruses-02-02493">24</xref>–
 <xref ref-type="bibr" rid="b27-viruses-02-02493">27</xref>]. Another study from Botswana reported a high incidence of K65R (30%) in subtype C patients who received d4T/ddI plus NVP or EFV [
 <xref ref-type="bibr" rid="b28-viruses-02-02493">28</xref>]. In a much larger study, results from Malawi detected K65R or K70E in 23% of patients failing first line therapy with d4T/3TC/NVP [
 <xref ref-type="bibr" rid="b26-viruses-02-02493">26</xref>], while K65R was detected in 7% and 15% of patients in South Africa failing first or second line regimens, respectively, whose nucleoside backbones included d4T/3TC or ddI/ZDV [
 <xref ref-type="bibr" rid="b29-viruses-02-02493">29</xref>–
 <xref ref-type="bibr" rid="b30-viruses-02-02493">30</xref>]. In addition, a study from Israel reported a high frequency of K65R in subtype C viruses from Ethiopian immigrants [
 <xref ref-type="bibr" rid="b31-viruses-02-02493">31</xref>]. Finally, a recent report from India has shown that K65R was present in about 10–12% of patients who had received d4T/3TC/NVP in first-line therapy [
 <xref ref-type="bibr" rid="b32-viruses-02-02493">32</xref>]. Differences in K65R and thymidine analogue mutations (TAMs) could be ascribed to treatment regimen and disease stage [
 <xref ref-type="bibr" rid="b24-viruses-02-02493">24</xref>–
 <xref ref-type="bibr" rid="b27-viruses-02-02493">27</xref>]. Access to viral load testing lead in India was associated with early detection of NNRTI-treatment failure, preventing acquisition of TAMs and K65R [
 <xref ref-type="bibr" rid="b24-viruses-02-02493">24</xref>]. Other studies support regional differences among subtype C sub-epidemics from Ethiopia, Brazil and sub Saharan Africa, that impact on the RT backbone and NRTI resistance rates [
 <xref ref-type="bibr" rid="b8-viruses-02-02493">8</xref>,
 <xref ref-type="bibr" rid="b33-viruses-02-02493">33</xref>–
 <xref ref-type="bibr" rid="b34-viruses-02-02493">34</xref>].
</p>
